Quarterly ResultMay 7, 2026, 04:19 PM
Intensity Therapeutics Reports Favorable INVINCIBLE-4 Data; $10.2M Cash
AI Summary
Intensity Therapeutics reported its first quarter 2026 financial results, showing a net loss of $2.4 million and cash and cash equivalents of $10.2 million as of March 31, 2026. The company provided a corporate update, highlighting favorable preliminary efficacy and safety data from its INVINCIBLE-4 Study in triple negative breast cancer, with enrollment now resuming. Additionally, Intensity Therapeutics plans to resume enrollment in its INVINCIBLE-3 Study for soft tissue sarcoma in limited U.S. sites by the third quarter of 2026, after a previous pause due to funding constraints.
Key Highlights
- Cash and cash equivalents totaled $10.2 million as of March 31, 2026.
- INVINCIBLE-4 Study showed 71.4% pCR (5/7 patients) in INT230-6 arm vs 33% (2/6 patients) in SOC arm.
- INVINCIBLE-4 Study reported 44% fewer grade 3 or higher adverse events in INT230-6 arm.
- Approval obtained to resume enrollment in INVINCIBLE-4 Study in Switzerland, with plans for France in Q2/Q3 2026.
- Decision made to resume enrollment in INVINCIBLE-3 Study in limited U.S. sites by Q3 2026.
- Net loss was $2.4 million for Q1 2026, compared to $3.3 million for Q1 2025.
- Research and development expenses decreased to $1.2 million in Q1 2026 from $2.2 million in Q1 2025.
- General and administrative expenses increased to $1.3 million in Q1 2026 from $1.2 million in Q1 2025.